Abstract
A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Letters in Drug Design & Discovery
Title: Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Volume: 7 Issue: 10
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Nasim Hasan Rama, Farzana Naz, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Abstract: A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Rasool Mughal Uzma, Ambreen Nida, Hasan Rama Nasim, Naz Farzana, Perveen Shahnaz and Iqbal Choudhary Muhammad, Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase, Letters in Drug Design & Discovery 2010; 7 (10) . https://dx.doi.org/10.2174/1570180811007010716
DOI https://dx.doi.org/10.2174/1570180811007010716 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Sequence Variants of the Ligand-Binding Domain of the Glucocorticoid Receptor Gene and their Functional Consequences on the Three- Dimensional Protein Structure
Current Medicinal Chemistry L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science The Enzymatic Technologies Open New Possibilities for Studying Nitric Oxide (NO) Metabolism in Living Systems
Current Enzyme Inhibition Overview of Murine Atherosclerosis Series
Current Drug Targets Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry The Concomitance of Hypertension and Diabetes Exacerbating Retinopathy: The Role of Inflammation and Oxidative Stress.
Current Clinical Pharmacology ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans
Current Drug Metabolism The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets